ASH 2022 | The advent of bispecific antibodies for multiple myeloma
Elena Zamagni
• 11 Dec 2022
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, shares her excitement for the advent of bispecific antibodies for multiple myeloma, commenting on their space in the myeloma treatment algorithm and highlighting remaining questions in this field. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, BMS, Amgen, Roche, Pfizer, Sanofi, GSK: Honoraria, Other.
